SYNDAX PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.24 USD | -0.26% |
|
-5.13% | -10.97% |
| May. 16 | Transcript : Syndax Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 08:00 AM | |
| May. 15 | Syndax Pharmaceuticals, Inc. Announces Board Changes | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 238.3 | 1,048 | 1,184 | 1,733 | 1,833 | 1,638 | - | - |
| Enterprise Value (EV) 1 | 178.5 | 754.9 | 981.6 | 1,249 | 1,255 | 1,593 | 1,435 | 1,543 |
| P/E ratio | -4.77 x | -11.9 x | 45.6 x | -10.3 x | -7.25 x | -5.41 x | -6.6 x | -9.03 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 157 x | 691 x | 8.47 x | - | - | 52 x | 15.2 x | 7.3 x |
| EV / Revenue | 118 x | 498 x | 7.03 x | - | - | 50.5 x | 13.3 x | 6.88 x |
| EV / EBITDA | -3.07 x | -10.6 x | 36.5 x | -8.05 x | -5.13 x | -4.78 x | -5.87 x | -9.66 x |
| EV / FCF | -3.53 x | -10.6 x | 33.8 x | -9.34 x | -7.82 x | -5.91 x | -8.34 x | -16.5 x |
| FCF Yield | -28.4% | -9.44% | 2.95% | -10.7% | -12.8% | -16.9% | -12% | -6.07% |
| Price to Book | 7.54 x | 4.22 x | - | 3.71 x | 2.74 x | 3.43 x | 2.78 x | 3.21 x |
| Nbr of stocks (in thousands) | 27,140 | 47,119 | 54,074 | 68,100 | 84,810 | 84,987 | - | - |
| Reference price 2 | 8.780 | 22.24 | 21.89 | 25.45 | 21.61 | 19.27 | 19.27 | 19.27 |
| Announcement Date | 3/3/20 | 3/8/21 | 3/1/22 | 2/28/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.517 | 1.517 | 139.7 | - | - | 31.52 | 108 | 224.4 |
| EBITDA 1 | -58.23 | -71.33 | 26.91 | -155.1 | -244.7 | -333.5 | -244.5 | -159.8 |
| EBIT 1 | -57.54 | -71.42 | 26.22 | -151.8 | -230 | -330.9 | -279.9 | -199.6 |
| Operating Margin | -3,792.95% | -4,708.17% | 18.77% | - | - | -1,049.59% | -259.22% | -88.94% |
| Earnings before Tax (EBT) 1 | -56.05 | -73.16 | 24.93 | -149.3 | -209.4 | -314.4 | -279.9 | -194.6 |
| Net income 1 | -56.05 | -77.06 | 24.93 | -149.3 | -209.4 | -306.8 | -269 | -205.7 |
| Net margin | -3,694.59% | -5,080.03% | 17.84% | - | - | -973.19% | -249.11% | -91.66% |
| EPS 2 | -1.840 | -1.870 | 0.4800 | -2.460 | -2.980 | -3.563 | -2.921 | -2.133 |
| Free Cash Flow 1 | -50.61 | -71.26 | 29 | -133.7 | -160.6 | -269.5 | -172 | -93.67 |
| FCF margin | -3,336.32% | -4,697.43% | 20.76% | - | - | -854.94% | -159.31% | -41.74% |
| FCF Conversion (EBITDA) | - | - | 107.79% | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | 116.35% | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/3/20 | 3/8/21 | 3/1/22 | 2/28/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 126.6 | - | - | - | - | - | - | - | - | - | - | 6.224 | 27.56 | 10.75 | 14.85 |
| EBITDA 1 | - | - | - | - | - | - | - | - | -81.36 | -83.33 | -82.44 | -94.81 | -66.42 | - | - |
| EBIT 1 | 95.75 | -36.86 | -37.72 | -35.14 | -42.03 | -46.02 | -49.68 | -56.36 | -77.9 | -79.51 | -82.99 | -88.37 | -77.82 | -91.8 | -89.75 |
| Operating Margin | 75.65% | - | - | - | - | - | - | - | - | - | - | -1,419.84% | -282.33% | -853.95% | -604.38% |
| Earnings before Tax (EBT) 1 | 96.2 | -37.17 | -37.57 | -35.4 | -39.19 | -41.13 | -44.62 | -51.15 | -72.47 | -72.4 | -77.88 | -77.38 | -86.88 | -88.3 | -89.2 |
| Net income 1 | 96.2 | -37.17 | -37.57 | -35.4 | -39.19 | -41.13 | -44.62 | -51.15 | -72.47 | -72.4 | -78.53 | -81.49 | -72.24 | -87.65 | -85.6 |
| Net margin | 76% | - | - | - | - | - | - | - | - | - | - | -1,309.33% | -262.06% | -815.35% | -576.43% |
| EPS 2 | 1.810 | -0.6300 | -0.6200 | -0.5800 | -0.6200 | -0.5900 | -0.6400 | -0.7300 | -1.000 | -0.8500 | -0.9200 | -0.9529 | -0.8343 | -1.030 | -1.005 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/1/22 | 5/9/22 | 8/8/22 | 11/3/22 | 2/28/23 | 5/8/23 | 8/3/23 | 11/2/23 | 2/27/24 | 5/8/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 59.8 | 293 | 202 | 484 | 578 | 44.3 | 203 | 94.5 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -50.6 | -71.3 | 29 | -134 | -161 | -270 | -172 | -93.7 |
| ROE (net income / shareholders' equity) | -132% | -54.3% | 7.55% | -34.1% | -41% | -60.3% | -63% | -32.5% |
| ROA (Net income/ Total Assets) | - | - | - | -31.5% | -37.7% | -56.3% | -45.2% | -29.5% |
| Assets 1 | - | - | - | 473.4 | 555.1 | 544.7 | 594.9 | 696.4 |
| Book Value Per Share 2 | 1.160 | 5.270 | - | 6.860 | 7.880 | 5.610 | 6.930 | 6.010 |
| Cash Flow per Share 2 | - | - | - | - | -2.280 | -2.710 | -0.8900 | - |
| Capex 1 | - | - | 0.13 | - | - | 3.75 | 1.7 | 1.7 |
| Capex / Sales | - | - | 0.09% | - | - | 11.9% | 1.57% | 0.76% |
| Announcement Date | 3/3/20 | 3/8/21 | 3/1/22 | 2/28/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
19.27
USD
Average target price
34.17
USD
Spread / Average Target
+77.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.97% | 1.64B | |
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B | |
| -11.83% | 10.74B |
- Stock Market
- Equities
- SNDX Stock
- Financials Syndax Pharmaceuticals, Inc.
